Results 21 to 30 of about 6,510 (175)

Poly(ADP-ribosylation) is present in murine sciatic nerve fibers and is altered in a Charcot-Marie-Tooth-1E neurodegenerative model [PDF]

PeerJ, 2017
Background Poly-ADP-ribose (PAR) is a polymer synthesized by poly-ADP-ribose polymerases (PARPs) as a postranslational protein modification and catabolized mainly by poly-ADP-ribose glycohydrolase (PARG).
Laura I. Lafon Hughes, Carlos J. Romeo Cardeillac, Karina B. Cal Castillo, Salomé C. Vilchez Larrea, José R. Sotelo Sosa, Gustavo A. Folle Ungo, Silvia H. Fernández Villamil, Alejandra E. Kun González   +7 more
doaj   +2 more sources

Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

Journal of Experimental & Clinical Cancer Research, 2021
Background Patients with ovarian cancer often present at advanced stage and, following initial treatment success, develop recurrent drug-resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival benefits for women with BRCA-deficient
Camilla Coulson-Gilmer, Robert D. Morgan, Louisa Nelson, Bethany M. Barnes, Anthony Tighe, René Wardenaar, Diana C. J. Spierings, Helene Schlecht, George J. Burghel, Floris Foijer, Sudha Desai, Joanne C. McGrail, Stephen S. Taylor   +12 more
doaj   +1 more source

5mC-hydroxylase activity is influenced by the PARylation of TET1 enzyme [PDF]

, 2015
5-hydroxymethylcytosine is a new epigenetic modification deriving from the oxidation of 5-methylcytosine by the TET hydroxylase enzymes. DNA hydroxymethylation drives DNA demethylation events and is involved in the control of gene expression ...
CAIAFA, Paola, CICCARONE, FABIO, VALENTINI, ELISABETTA, ZAMPIERI, Michele   +3 more
core   +9 more sources

PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment

Pathology & Oncology Research, 2010
Today, the number of cancer patients throughout the world is increasing alarmingly and as per the World Health Organisation (WHO) data and statistics the prediction for the year 2020 will be 15 million new cases as compared to only 10 million cases in year 2000 leaving us dumbfounded.
Nilufer Jasmine Selimah, Fauzee, Juan, Pan, Ya-lan, Wang   +2 more
openaire   +2 more sources

Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury

Frontiers in Bioscience, 2007
Cumulative evidence has indicated a critical role of poly(ADP-ribose) polymerase-1 activation in ischemic brain damage. Poly(ADP-ribose) glycohydrolase (PARG) is a key enzyme in poly(ADP-ribose) catabolism. Our previous studies showed that PARG inhibitors, gallotannin (GT) and nobotanin B, can profoundly decrease oxidative cell death in vitro. Here, we
Wei, Guangwei, Wang, Dongmin, Lu, Huafei, Parmentier, Sophie, Wang, Qing, Panter, S. Scott, Frey II, William H., Ying, Weihai   +7 more
openaire   +4 more sources

The importance of Poly(ADP-Ribose) Polymerase as a sensor of unligated Okazaki fragments during DNA replication [PDF]

, 2018
Poly(ADP-ribose) is synthesized by PARP enzymes during the repair of stochastic DNA breaks. Surprisingly, however, we show that most if not all endogenous poly(ADP-ribose) is detected in normal S phase cells at sites of DNA replication. This S phase poly(
Caldecott, Keith W, Cihlarova, Zuzana, Demin, Annie A, Hanzlikova, Hana, Kalasova, Ilona, Pennicott, Lewis E   +5 more
core   +1 more source

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]

, 2016
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide, Papa, Anselmo, Strudel, Martina, Tomao, Federica, Tomao, Silverio   +4 more
core   +2 more sources

Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma [PDF]

, 2020
AbstractGlioblastoma (GBM) is the most aggressive primary adult brain tumor, with a median survival of approximately 15 months. Despite novel therapeutic approaches, median survival has remained largely unchanged since the standard of care therapy for GBM was established nearly 15 years ago.
Henre Hermanowski, Barbara Huebert, Christopher Aldrighetti, Jenna K Hurley, Delphine Quénet   +4 more
openaire   +1 more source

Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei [PDF]

, 2016
TbPARG in Trypanosoma brucei. A) TbPARG localization in untreated (control) and in procyclic cultures exposed to 500 μM H2O2 for 10 min. IFI was carried out as reported in our previous work [33].
Harikanth Venkannagari, Lari Lehtiö, Mariana Schlesinger, Mirtha M. Flawiá, Mohit Narwal, Salomé C. Vilchez Larrea, Silvia H. Fernández Villamil, Teemu Haikarainen   +7 more
core   +6 more sources

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors [PDF]

Cancer Research, 2017
Abstract The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity of PDAC cells to PARP inhibitors (PARPi).
Chand, Saswati N., Zarei, Mahsa, Schiewer, M. J., Sanan, Akshay R., Romeo, Carmella, Lal, Shruti, Cozzitorto, Joseph A., Nevler, Avinoam, Scolaro, Laura, Londin, Eric R., Jiang, Wei, Meisner-Kober, Nicole, Pishvaian, Michael J., Knudsen, Karen E., Yeo, Charles, Pascal, John M, Winter, Jordan M., Brody, Jonathan R.   +17 more
openaire   +2 more sources